- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01829958
전단계 치료의 내장 파일럿 연구를 통해 비호지킨 림프종을 가진 고령 환자의 독성 사건을 예측하기 위한 종합적인 노인병 평가
This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, 미국, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, 미국, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, 미국, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, 미국, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center
-
Rockville Centre, New York, 미국, 11570
- Memorial Sloan Kettering Rockville Centre
-
Uniondale, New York, 미국, 11553
- Memorial Sloan Kettering Nassau
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Subjects meeting the following criteria will be eligible for enrollment in the study (unless excluded):
- ≥60 years old
- Pathologically confirmed NHL.
- Must meet criteria for initiation of treatment; consisting of:
- Aggressive histology, or
- Indolent histology with one of the following markers of large tumor burden (67):
- Any nodal or extranodal tumor mass ≥7cm in greatest dimension
- ≥3 nodal masses that are each ≥3 cm in greatest dimension
- Systemic symptoms
- Cytopenias (leukocytes <1 × 109/L and/or platelets ,100 × 109/L)
- Substantial splenomegaly
- Serous effusion (plural effusion or peritoneal ascites)
- Orbital or epidural involvement
- Ureteral compression
- Leukemic phase (malignant cells ≥5 x 109/L)
- Must be starting a new chemotherapy regimen (patients whose treatment regimen includes an immunomodulatory agent such as lenalidomide or small molecule targeted agents such as Ibrutinib or Idelelasib will be included in the study; patients being treated with a single agent monoclonal antibody will not be included).
- Fluent in English (because not all components of the GA have been validated in other languages)
- Able to provide informed consent
In addition to the above, subjects meeting the following criteria will be enrolled in the pre-phase arm of the study, until the accrual target for that arm is reached:
- Age ≥ 70 years OR KPS ≤ 70
- Pathologically confirmed diagnosis of DLBCL, with or without simultaneous or antecedent indolent lymphoma.
- Previously untreated for DLBCL
- Intended initial treatment to include ≥2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days. (4, 70)
Exclusion Criteria:
Subjects meeting the following criteria will be excluded from enrollment in the study:
- Enrollment in a Phase I trial
- Previously enrollment in this study
- Patients scoring ≥ 11 on the BOMC (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Subjects meeting the following criteria will be excluded from enrollment in the pre-phase arm of the study, but may be included in the GA only arm.
- Contraindication to use of rituximab or prednisone including:
- Uncontrolled diabetes mellitus
- Systemic fungal infection
- Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B surface antigen or viral DNA by PCR analysis) will be excluded. Patients with evidence of past infection without active viremia (i.e. positive hepatitis B core antibody, negative hepatitis B surface antigen and negative hepatitis B DNA PCR) will be treated with entecavir as per institutional guidelines and may be included in the study.
- History of any serious adverse reaction to either a corticosteroid or rituximab not including rituximab infusion reactions ≤ Grade 3.
- Patients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its components.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Pre-Phase Arm
They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol. |
|
|
실험적: Geriatric Assessment (GA) only arm
Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Toxicity Assessment
기간: 3 years
|
Hospitalization during or within 30 days following chemotherapy Dose delay or reduction to a dose intensity ≤80% of the planned dose intensity. Dose reductions occurring prior to cycle 1 of chemotherapy will be counted as events. Discontinuation of chemotherapy due to toxicity Grade 3 or higher non-hematologic toxicity Grade 4 or higher hematologic toxicity. Using the NCI CTCAE v4.0 toxicity grading |
3 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Paul Hamlin, MD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 림프종, B세포
- 림프종
- 헴 및 림프병
- 림프종, 대형 B세포, 미만성
- 림프종, 비호지킨
- 건강 관리 품질, 접근 및 평가
- 아미노산, 펩티드 및 단백질
- 단백질
- 조사 기술
- 역학적 방법
- 데이터 수집
- 건강 관리 평가 메커니즘
- 건강 관리의 질
- 공중 위생
- 환경 및 공중 보건
- 다 환식 화합물
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- Pretadienes
- 임신
- 스테로이드
- 융합 링 화합물
- 인구 특성
- 건강 상태
- 인구 통계학
- Pregnadienediols
- 역학 측정
- 항체, 모노클로 날, 뮤린 유래
- 리툭시맙
- 프레드니손
- 노인 평가
기타 연구 ID 번호
- 13-028
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .